Related Experiment Video

Updated: Mar 28, 2026

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

4.6K

Does high serum uric acid level cause aspirin resistance?

Bekir S Yildiz1, Emel Ozkan, Fatma Esin

  • 1aDepartment of Cardiology, Pamukkale University, DenizlibIzmir Ataturk Training and Research HospitalcIzmir Bozyaka Training and Research Hospital, IzmirdDepartment of Cardiology, Diskapi Training and Research Hospital, AnkaraeDepartment of Public Health, Pamukkale University, Denizli, Turkey.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|December 15, 2015
PubMed

Insights

High serum uric acid (SUA) levels may indicate aspirin resistance in patients with coronary artery disease (CAD). This finding suggests that elevated SUA could predict aspirin resistance, potentially guiding treatment adjustments to prevent cardiovascular events.

Area of Science:

  • Cardiology
  • Clinical Biochemistry
  • Pharmacology

Background:

  • Aspirin resistance, a failure to inhibit platelet function, is a clinical concern in coronary artery disease (CAD).
  • Hyperuricemia, indicated by elevated serum uric acid (SUA) levels, is known to activate platelet turnover.
  • A potential link exists between hyperuricemia and aspirin resistance in CAD patients.

Purpose of the Study:

  • To investigate the association between serum uric acid (SUA) levels and aspirin resistance in patients with coronary artery disease (CAD).
  • To determine if high SUA levels are an independent predictor of aspirin resistance.

Main Methods:

  • Analysis of 245 consecutive patients with stable angina pectoris (SAP) and significant coronary artery occlusion.
  • Classification of patients into aspirin-resistant (Group 1) and aspirin-sensitive (Group 2) groups.
  • Multivariate analysis and receiver-operating characteristic (ROC) analysis to identify predictors and cutoff values for SUA.

Main Results:

  • Patients with aspirin resistance showed significantly higher white blood cell counts, neutrophil counts, neutrophil-to-lymphocyte ratios, SUA levels, high-sensitivity C-reactive protein, and fasting blood glucose.
  • Elevated SUA levels were identified as an independent predictor of aspirin resistance.
  • ROC analysis indicated a SUA cutoff value of 6.45 mg/dL for predicting aspirin resistance with 79% sensitivity and 65% specificity.

Conclusions:

  • Hyperuricemia may contribute to aspirin resistance in patients with CAD.
  • High SUA levels can serve as an indicator for aspirin resistance in this population.
  • Monitoring SUA levels could inform adjustments in aspirin dosage to mitigate risks of heart attack and stroke.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
61
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
330
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
2.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68